Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-659 pembrolizumab plus TS-1 and platinum in first-line advanced gastric cancer
jRCT2080223773Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2018
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab, tegafur, oxaliplatin and cisplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Merck & Co. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080223773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223773.